{"filings":[{"id":1194759,"accession_number":"0001193125-26-277505","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2026-06-22T20:05:16+00:00","items":["1.01"],"status":"ready","headline":"AnaptysBio subleases 45,057 sq ft of HQ to First Tracks for up to ~22 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sublease of 45,057 rentable sq ft at 10770 Wateridge Circle, San Diego, for 12-month initial term starting June 15, 2026.","First Tracks has option to extend term until April 4, 2028 (max ~22 months) and can terminate with 3 months' notice.","Sublessee pays Basic Rent plus Additional Rent under master lease; AnaptysBio remains primarily liable to master landlord.","Sublease is subordinate to master lease; AnaptysBio cannot terminate or amend master lease without First Tracks' consent (except for its own termination option)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":746878,"accession_number":"0001193125-26-248326","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2026-05-29T20:15:16+00:00","items":["7.01"],"status":"ready","headline":"AnaptysBio files Form 8937 with IRS regarding tax treatment of First Tracks spin-off dividend","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Form 8937 with IRS concerning dividend from separation and spin-off of First Tracks Biotherapeutics.","Form 8937 provides guidance on how the dividend is treated by stockholders and change in tax basis.","Form 8937 information will be posted on AnaptysBio's website under the Investors section.","Company urges stockholders to consult their own tax advisor regarding tax consequences of the distribution.","This update is for informational purposes only and not to be considered legal or tax advice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":581958,"accession_number":"0001193125-26-234419","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2026-05-21T20:10:15+00:00","items":["5.03"],"status":"ready","headline":"AnaptysBio changes fiscal year-end from Dec 31 to June 30, effective July 1, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved fiscal year change from December 31 to June 30, effective July 1, 2026.","Company will file a transition report on Form 10-KT for the six-month period Jan 1, 2026 to June 30, 2026.","Quarterly reports will follow new fiscal year, beginning with the quarter ending September 30, 2026.","Change is effective for the company's next fiscal year starting July 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40727,"accession_number":"0001193125-26-219500","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2026-05-12T20:17:24+00:00","items":["2.02","9.01"],"status":"ready","headline":"AnaptysBio Q1 net loss $52.9M; completes First Tracks spin-off, Jemperli royalties up 44%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $1.84 vs $1.28 YoY; collaboration revenue $25.6M (Jemperli royalties $24.7M, +44%).","Cash $286.5M at March 31; stock repurchase plan of $100M authorized through Dec 31, 2026.","Spin-off of First Tracks Bio completed Apr 20; now exclusively manages Jemperli (GSK) and imsidolimab (Vanda) financial collaborations.","Expects >$390M annualized Jemperli royalties by 2029 at GSK's >$2.7B peak sales; Sagard debt paydown by Q2 2027.","FDA PDUFA Dec 12, 2026 for imsidolimab in GPP; Chris Murphy appointed CFO, Susannah Gray and Owen Hughes to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":25556000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12887,"accession_number":"0001193125-26-216745","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2026-05-11T20:05:24+00:00","items":["5.02"],"status":"ready","headline":"AnaptysBio appoints Christopher Murphy CFO ($42,917/mo) and Owen Hughes to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Murphy appointed CFO effective May 11, 2026; previously CFO at Third Harmonic Bio and Horizon Therapeutics.","Murphy's consulting agreement: $42,916.66 monthly fee, target bonus up to 40% of annual fees, and $1.75M RSU grant vesting over 4 years.","Owen Hughes appointed Class I director effective May 11, 2026; receives initial grant of 11,250 RSUs vesting over 3 years.","Murphy serves as independent contractor; severance provides 9-12 months fee continuation based on termination cause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92457,"accession_number":"0001193125-26-177317","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K/A","filed_at":"2026-04-24T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"AnaptysBio pro forma continuing ops net income $114.9M after First Tracks spin-off","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pro forma continuing ops net income $114.9M for FY2025; basic EPS $3.99, diluted $3.07.","Collaboration revenue $234.6M, operating income $217.9M after spin-off adjustments.","AnaptysBio provided $100M cash distribution to First Tracks; expects $7M non-recurring costs within 12 months.","Pro forma balance sheet as of Dec 31, 2025 shows negative stockholders' equity of $116.3M.","First Tracks shares began trading on Nasdaq under ticker TRAX on April 20, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92458,"accession_number":"0001193125-26-164330","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["1.01","2.01","5.02","8.01","9.01"],"status":"ready","headline":"AnaptysBio completes spin-off of First Tracks Biotherapeutics (TRAX); distribution effective April 20, 2026","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Each ANAB shareholder received one TRAX share for each share held on record date April 6, 2026.","First Tracks started trading on Nasdaq under ticker TRAX on April 20, 2026.","AnaptysBio retains royalty management for dostarlimab (Jemperli) and imsidolimab from Vanda.","First Tracks receives $100M cash, up to $35M in Vanda milestones, and clinical assets rosnilimab, ANB033, ANB101.","Separation and Distribution Agreement allocates assets/liabilities between royalty management and biotech businesses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103308,"accession_number":"0001193125-26-127783","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["1.01","1.02","5.02","7.01","9.01"],"status":"ready","headline":"AnaptysBio approves spin-off of First Tracks Biotherapeutics; distribution set for April 20, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anaptys stockholders to receive one share of First Tracks Bio (TRAX) per ANAB share held on April 6, 2026; distribution expected pre-market April 20, 2026.","First Tracks Bio launches with $180M cash ($100M from Anaptys + $80M from private placement at $13.81/share) and a two-year cash runway.","Post-spin Anaptys to manage Jemperli (GSK) and imsidolimab (Vanda) royalties; virtual model with <10 FTEs and <$10M annual opex; $100M stock repurchase plan authorized.","Susannah Gray (former Royalty Pharma CFO) appointed to Anaptys board; Dennis Mulroy and Eric Loumeau to exit with separation agreements.","Anaptys terminates existing ATM sales agreement with TD Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103307,"accession_number":"0001193125-26-088239","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AnaptysBio plans spin-off of biopharma as First Tracks (TRAX); Q4 net income $49.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Spin-off of biopharma portfolio into First Tracks Biotherapeutics (TRAX) on track for Q2 2026, potentially late April.","Q4 2025 net income $49.6M ($1.79 EPS); full year net loss $13.2M ($0.46 loss per share).","Collaboration revenue Q4 $108.2M (up from $43.1M); Jemperli royalties $32.7M (+89% YoY).","GSK Jemperli Q4 sales $343M, annualized ~$1.4B; peak sales guidance >$2.7B; expect >$390M annual royalties.","Cash $311.6M at year-end; stock repurchased 3.44M shares for $68.6M under program expiring March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103306,"accession_number":"0001370053-26-000002","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AnaptysBio reports preliminary cash & investments of ~$310M as of Dec 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, equivalents and investments ~$310M as of Dec 31, 2025.","Audited FY2025 financials not yet available; final results may differ materially.","Disclosure to be made at J.P. Morgan Healthcare Conference on January 11, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119561,"accession_number":"0001370053-25-000103","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AnaptysBio sues Tesaro and GSK for breach of collaboration agreement on dostarlimab","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["AnaptysBio filed suit in Delaware Chancery Court on Nov 20, 2025, alleging material breach of the Collaboration Agreement by Tesaro and GSK.","Complaint seeks declaration that rights to dostarlimab revert to AnaptysBio within 60 days of notice of material breach.","Allegations include Tesaro/GSK conducting clinical trials with competing PD-1 (Keytruda) instead of optimizing dostarlimab's commercial return, and failing to disclose trials.","This follows a 2020 settlement where Tesaro/GSK paid $60M and doubled royalties; AnaptysBio claims violations continued post-settlement.","Tesaro and GSK filed a counterclaim on Nov 26, 2025, claiming AnaptysBio breached the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119560,"accession_number":"0001370053-25-000097","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Board authorizes $100M increase in stock repurchase plan; $106.4M total capacity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board amended Stock Repurchase Plan to allow up to $100M additional repurchases, plus $6.4M remaining under prior $75M plan.","Anaptys has repurchased 3,443,188 shares (11.2% of shares outstanding) under the plan to date.","Company expects ~$300M cash end-2025, including anticipated $75M commercial milestone from GSK on Jemperli reaching $1B sales.","Plan expires March 31, 2026; repurchases depend on market conditions and regulatory limitations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119559,"accession_number":"0001370053-25-000096","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AnaptysBio sues Tesaro and GSK for breach of Jemperli collaboration; countersuit filed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AnaptysBio alleges Tesaro breached exclusivity by conducting trials with competing PD-1 antagonists (e.g., Keytruda) and failing to maximize Jemperli return.","Tesaro countersued AnaptysBio on Nov 20, 2025, seeking injunctive relief; AnaptysBio calls claims meritless and will seek dismissal.","Parties agreed to expedited Delaware Chancery Court schedule; trial anticipated July 2026.","Milestone and royalty payments under Collaboration Agreement remain due during litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119558,"accession_number":"0001370053-25-000091","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"AnaptysBio's rosnilimab fails Phase 2 UC trial; trial discontinued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rosnilimab did not meet primary (mMS change) or key secondary endpoints at Week 12 in moderate-to-severe UC.","Clinical remission 7% for both doses vs 5% and 4% endoscopic remission; placebo rates within historical ranges.","Trial discontinued saving at least $10M; update on rosnilimab in RA expected H1 2026 via strategic capital.","Reaffirms 2026 separation of biopharma from royalty assets; Jemperli royalties >$390M/yr at peak sales >$2.7B.","Expects ~$300M cash end-2025 including $75M milestone from GSK for Jemperli reaching $1B global net sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119557,"accession_number":"0001370053-25-000088","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AnaptysBio plans to separate biopharma ops from royalty assets by YE 2026; Q3 net income $15.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Intent to split into two public companies, one holding Jemperli royalties and milestones, the other advancing pipeline assets.","Q3 2025 revenue $76.3M (up from $30.0M), net income $15.1M ($0.54/share) vs net loss of $32.9M in Q3 2024.","Cash and investments $256.7M; expects ~$300M YE 2025 including $75M milestone from GSK when Jemperli hits $1B sales.","Phase 2 top-line data for rosnilimab in ulcerative colitis expected Nov/Dec 2025; Phase 2b RA data positive.","GSK's Jemperli Q3 sales $303M (+16% QoQ); annualized royalties for Anaptys >$390M at peak guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119556,"accession_number":"0001370053-25-000083","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AnaptysBio holds ANB033 (CD122 antagonist) investor event; updates corporate presentation","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Conference call and slide presentation on ANB033 (CD122 antagonist) held on October 14, 2025.","Updated corporate investor presentation filed as Exhibit 99.2; no specific clinical or financial data disclosed in the filing text.","Event intended to provide pipeline update; details of ANB033 discussion not expanded in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136127,"accession_number":"0001370053-25-000081","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"AnaptysBio to split into two public companies by end of 2026; royalty assets separate from biopharma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Daniel Faga expected to lead Biopharma Co; Royalty Co holds Jemperli (GSK) and imsidolimab (Vanda) royalties.","Jemperli royalties tiered: 8% up to $1B sales, 12% $1-1.5B, 20% $1.5-2.5B, 25% above $2.5B; GSK peak sales guide >£2B.","Sagard monetization capped at $600M; expected paydown mid-2027 to Q2 2028.","Biopharma Co pipeline: rosnilimab (Phase 2b RA, Phase 2 UC top-line Nov/Dec 2025), ANB033 (celiac Ph1b), ANB101 (Ph1a).","Separation targeted by year-end 2026; taxable but minimizing taxes; subject to board and SEC approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136126,"accession_number":"0001370053-25-000063","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AnaptysBio Q2 net loss narrows to $38.6M; rosnilimab Phase 2b RA data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.6M ($1.34/sh) vs $46.7M ($1.71) YoY; collaboration revenue $22.3M, up from $11.0M.","Cash & investments $293.7M as of June 30, 2025; cash runway through year-end 2027 reiterated.","Rosnilimab RA Phase 2b shows JAK-like efficacy, durable off-drug response; UC Phase 2 enrollment complete, top-line Q4 2025.","ANB033 (CD122 antagonist) to begin Phase 1b in celiac disease by Q4 2025; R&D event planned.","Anticipate $75M GSK milestone in 2025 once Jemperli achieves $1B annual net sales."],"consensus_eps_estimate":-1.5725,"consensus_eps_actual":-2.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":50034000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153182,"accession_number":"0001370053-25-000055","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"AnaptysBio shareholders approve amended equity plan, elect directors at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Rita Jain, John Orwin, and J. Anthony Ware as Class II directors for three-year terms with over 21M votes for each.","Approved amendment to 2017 Equity Incentive Plan with 18.0M for, 6.4M against; increases share reserve to 13.5M shares.","Ratified KPMG as independent auditor for FY2025 with 27.2M votes for, 17K against.","Advisory say-on-pay passed with 17.8M for, 6.6M against; shareholders preferred one-year frequency for future votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153181,"accession_number":"0001370053-25-000052","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"AnaptysBio rosnilimab Phase 2b RA data shows best-in-disease profile with JAK-like efficacy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["424-patient Phase 2b trial: rosnilimab achieved JAK-like efficacy on CDAI LDA, remission, and ACR70 through six months.","Favorable safety: no treatment-related SAEs, <2% discontinuation due to AEs, low injection site reactions.","Responses durable for at least 2 months off drug; pain VAS improved ~50 points from baseline ~65 to ~15.","69% of patients achieved CDAI LDA by Week 14; max response rates not yet observed due to strict continuation criteria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153180,"accession_number":"0001370053-25-000045","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AnaptysBio Q1 net loss $39.3M ($1.28/sh); rosnilimab Phase 2b RA data positive; $75M buyback authorized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $383M as of March 31, 2025, with cash runway through year-end 2027.","Collaboration revenue $27.8M (up from $7.2M YoY), driven by Jemperli royalties and Vanda license.","R&D expenses $41.2M, up from $37.0M YoY, primarily due to rosnilimab RA/UC and preclinical programs.","Rosnilimab achieved highest-ever CDAI LDA response in 424-patient Phase 2b RA trial; six-month data surpassed competitors.","Initial Phase 2 UC data for rosnilimab expected Q4 2025; GSK Jemperli $1B sales milestone still anticipated 2025/2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":27771000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171960,"accession_number":"0001370053-25-000028","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AnaptysBio authorizes up to $75M stock repurchase plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized $75M buyback of outstanding common stock.","Company holds >$420M cash as of Dec 2024; expects $75M GSK milestone in 2025/2026.","Reiterates cash runway through year-end 2027, excluding potential GSK royalties.","Repurchases via open market under Rule 10b5-1; plan expires Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171959,"accession_number":"0001370053-25-000023","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AnaptysBio reports positive rosnilimab RA data; Q4 net loss narrows to $21.8M; cash $420.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Rosnilimab achieved statistical significance on primary endpoint (DAS28-CRP) at Week 12 in Phase 2b RA trial; highest-ever CDAI LDA responses reported.","Exclusive global license with Vanda for imsidolimab: $15M upfront, up to $35M milestones, 10% royalty on net sales.","Cash and investments $420.8M at Dec 31, 2024; cash runway reiterated through year-end 2027.","Collaboration revenue from GSK Jemperli milestones $43.1M in Q4 and $91.3M in FY2024; Jemperli 2024 sales $598M (>200% growth).","Net loss $21.8M in Q4 ($0.72 loss per share) vs $42.2M in prior year; FY2024 net loss $145.2M ($5.12 per share)."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":91280000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171958,"accession_number":"0001370053-25-000014","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"AnaptysBio updates corporate investor presentation; details not available from filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing indicates updated February 2025 corporate presentation, but full content not provided in extract.","No specific financial or pipeline updates disclosed in the filing text or the partial exhibit.","Presentation typically covers strategic overview; no material numbers or events are reported.","Investors should refer to the full presentation on the company website for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171957,"accession_number":"0001370053-25-000010","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"AnaptysBio reports Phase 2b RA trial success; rosnilimab hits primary endpoint, 69% CDAI LDA at week 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b RENOIR trial (n=424) met primary endpoint (mean DAS-28 CRP change at week 12) across all three doses vs placebo (p<0.01).","At week 14, 69% of rosnilimab-treated patients achieved CDAI low disease activity, described as highest ever reported.","Favorable safety: no malignancies, no MACE, no serious infection elevation vs placebo; discontinuations low at 1-2%.","Full week 28 data expected Q2 2025; top-line week 12 rosnilimab UC data now anticipated in Q4 2025.","CEO states results exceed target product profile in ~$20B U.S. RA market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171956,"accession_number":"0001370053-25-000002","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["1.01","7.01"],"status":"ready","headline":"AnaptysBio licenses imsidolimab to Vanda for $15M upfront; BLA/MAA prep underway","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Anaptys receives $10M upfront and $5M for drug supply; eligible for up to $35M in milestones and 10% royalty on net sales.","Imsidolimab, an IL-36R antagonist, completed two global Phase 3 trials (GEMINI-1 and GEMINI-2) in Generalized Pustular Psoriasis.","Vanda plans to begin BLA and MAA submissions in the US and EU in 2025, leveraging its rare disease and anti-inflammatory expertise.","Positive Phase 3 data showed rapid disease clearance after single dose, maintained clear skin for at least 24 weeks with no safety signals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188954,"accession_number":"0001370053-24-000067","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AnaptysBio Phase 2B trial of ANB032 fails endpoints in atopic dermatitis; cash ~$415M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ANB032 did not meet primary endpoint EASI-75 or any secondary endpoints at Week 14 in 201-patient ARISE-AD trial.","Higher placebo rates than historical norms, particularly in U.S., contributed to failure; drug well tolerated with no safety signals.","Cash, equivalents and investments expected to be ~$415M at Dec 31, 2024, funding operations through year-end 2027.","One serious adverse event (worsening AD) across active arms; no dose relationship or imbalance in adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188953,"accession_number":"0001370053-24-000053","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AnaptysBio Q3 net loss $1.14/shr; cash $458M; Phase 2b data catalysts ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $32.9M ($1.14/shr) vs $37.3M ($1.41/shr) year-ago; nine-month loss $4.46/shr.","Collaboration revenue $30M in Q3 vs $3.3M year-ago due to Jemperli milestone and royalties.","Cash and investments $458M; reaffirms cash runway through year-end 2026.","Top-line Phase 2b data for ANB032 in atopic dermatitis expected December 2024.","Top-line Phase 2b data for rosnilimab in RA expected February 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":48167000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205428,"accession_number":"0001193125-24-200684","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"AnaptysBio prices public offering of 2.75M shares at $36.50 for ~$100M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$100M from sale of 2,750,498 shares at $36.50 per share.","Net proceeds to fund general corporate purposes including Phase III readiness of ANB032 and rosnilimab.","Offering expected to close on August 15, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205427,"accession_number":"0001370053-24-000039","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AnaptysBio Q2 net loss $46.7M; cash $393.5M; ANB032 Phase 2b enrollment complete, data Dec 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $46.7M ($1.71 per share) for Q2 2024, vs $39.8M loss ($1.50) in Q2 2023.","Cash & investments $393.5M as of June 30, 2024; runway reiterated through year-end 2026.","Completed enrollment (~200 patients) for ANB032 Phase 2b in atopic dermatitis; top-line data expected Dec 2024.","Rosnilimab Phase 2b RA top-line data accelerated to Q1 2025; Phase 2 UC data now expected Q1 2026.","IND for ANB033 (anti-CD122) accepted by FDA; Phase 1 trial initiation anticipated in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":18150000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222338,"accession_number":"0001370053-24-000029","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"AnaptysBio shareholders elect three Class I directors and approve equity plan amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Daniel Faga, Dennis Fenton, and Oleg Nodelman elected as Class I directors with 22.3M, 21.9M, and 18.8M votes for, respectively.","Ratification of KPMG as independent auditor for FY 2024 approved with 24.7M shares for, 30k against.","Non-binding advisory vote on executive compensation passed with 19.9M for, 2.95M against.","Amendment and restatement of 2017 Equity Incentive Plan approved with 16.8M for, 4.7M against, 1.3M abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222337,"accession_number":"0001370053-24-000026","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AnaptysBio Q1 net loss $43.9M, cash $370M; Phase 2b data for ANB032 by YE2024, $50M royalty monetization","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 net loss $43.9M ($1.64/share) vs $44.3M ($1.58/share) in Q1 2023; revenue $7.2M from Jemperli royalties.","Cash, cash equivalents, investments total $370.1M (excl. $50M monetization); cash runway through year-end 2026.","Phase 2b trial for ANB032 (BTLA agonist) in atopic dermatitis enrolling; top-line data expected by year-end 2024.","Phase 2b trial for rosnilimab (PD-1 agonist) in RA and Phase 2 trial in UC enrolling; top-line data mid-2025 and H1 2026.","Announced $50M capped non-recourse royalty monetization from Sagard for additional Jemperli royalties; positive Phase 3 imsidolimab results in GPP."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":7179000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241866,"accession_number":"0001370053-24-000010","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AnaptysBio reports Q4 2023 net loss of $42.2M, cash $417.9M; pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $42.2M ($1.59 per share); full-year net loss $163.6M ($6.08 per share).","Cash & investments $417.9M at Dec 31, 2023 (down from $584.2M year-end 2022); runway through 2026.","R&D spend $33.5M in Q4, up 43% YoY, driven by rosnilimab, ANB032, and ANB033 manufacturing.","ANB032 Phase 2b atopic dermatitis top-line data expected by year-end 2024; rosnilimab RA data mid-2025, UC data H1 2026.","IND filings for ANB033 (anti-CD122) in Q2 2024 and ANB101 (BDCA2) in H2 2024; ANB101 licensed for $7M upfront."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241865,"accession_number":"0001370053-24-000003","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AnaptysBio expects $417M cash at year-end 2023; presents at JPM Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Preliminary cash, cash equivalents, and investments of approximately $417M as of December 31, 2023.","Presentation at J.P. Morgan Healthcare Conference on January 8, 2024; full corporate overview furnished as Exhibit 99.1.","Audited FY2023 financials not yet available; preliminary estimate subject to adjustment.","Presentation details (pipeline, clinical data) not fully available in the provided exhibit excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259309,"accession_number":"0001370053-23-000069","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["1.01","7.01"],"status":"ready","headline":"AnaptysBio licenses global rights to BDCA2 modulator antibody portfolio from Centessa for $7M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $7M ($4M license fee + $3M for GMP supply of ANB101).","Centessa eligible for $10M milestone at first Phase 3 start and low single-digit royalties.","Anaptys plans to file IND for ANB101 in H2 2024; ANB033 IND expected H1 2024.","Reiterates year-end 2023 cash of $400–410M and cash runway through end of 2026.","ANB101 targets BDCA2 on plasmacytoid dendritic cells for autoimmune/inflammatory diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259308,"accession_number":"0001370053-23-000064","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AnaptysBio Q3 net loss $37.3M ($1.41/sh); imsidolimab Phase 3 GPP hits primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.3M ($1.41/sh) vs $33.5M ($1.18/sh) YoY; R&D spend rose to $30.9M.","Cash $453.3M at Sep 30, down $130.9M; reaffirms cash runway through year-end 2026.","Imsidolimab Phase 3 GPP: 53.3% achieved GPPPGA 0/1 vs 13.3% placebo (p=0.0131); out-license planned in 2024.","Initiated Phase 2b rosnilimab RA trial (420 pts); Phase 2 UC trial starting Q4 2023; top-line mid-2025 and H1 2026.","Collaboration revenue from Jemperli royalties $3.3M (vs $1.3M) helped offset net loss expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":8152000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259307,"accession_number":"0001370053-23-000058","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AnaptysBio presents R&D slide deck on PD-1 agonist rosnilimab","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presented rosnilimab (PD-1 agonist) R&D slide presentation on October 25, 2023.","No specific clinical data, milestones, or financial guidance disclosed in the filing.","Presentation provided as Exhibit 99.1; not filed, only furnished under Regulation FD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259306,"accession_number":"0001370053-23-000054","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AnaptysBio reports positive Phase 3 GEMINI-1 trial for imsidolimab in GPP; 53.3% vs 13.3% placebo at Week 4","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["53.3% of imsidolimab-treated patients achieved GPPPGA 0/1 at Week 4 vs 13.3% placebo (p=0.0131).","No SAEs or severe AEs in imsidolimab-treated patients; low infection rate vs placebo.","Only 3.3% had detectable non-neutralizing ADA.","Plans to file BLA with FDA by Q3 2024 and out-license imsidolimab in 2024.","Comprehensive data from GEMINI-1 and top-line GEMINI-2 expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276569,"accession_number":"0001370053-23-000052","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AnaptysBio Chairman James Topper resigns; John Orwin named Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Topper resigned as Class II director and Chairman effective Sept 15, 2023; no disagreement with company.","Topper will serve as advisor to the Board through Q1 2024 under an Advisory Agreement.","John Orwin appointed Class II director and Chairman on Sept 15, 2023.","Orwin received initial equity grants: option for 3,311 shares (vesting monthly to Jan 2024) and 2,035 RSUs (vest at 2024 annual meeting).","Orwin also granted option for 10,600 shares (3-year monthly vest) and 3,900 RSUs (3-year annual vest)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276568,"accession_number":"0001370053-23-000048","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AnaptysBio Q2 net loss $39.8M; imsidolimab Phase 3 enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $39.8M ($1.50/sh) vs $32.6M ($1.15) YoY; six-month loss $84.1M ($3.08/sh).","Completed enrollment of GEMINI-1 Phase 3 for imsidolimab in GPP; top-line data expected Q4 2023.","Cash and investments $488.7M at June 30; updated year-end 2023 guidance $380-395M; runway through 2026.","Initiating global Phase 2b for rosnilimab in RA in Q3 2023; second Phase 2 trial by year-end.","Daniel Faga appointed permanent president and CEO; new SAB members added."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":4834000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294330,"accession_number":"0001370053-23-000043","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"AnaptysBio shareholders elect three directors, ratify KPMG, approve executive pay, and amend charter","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Magda Marquet (21.6M for), Hollings Renton (16.9M for), John P. Schmid (20.4M for) as Class III directors for three-year terms.","Ratified KPMG LLP as independent auditor for FY2023 with 24.5M for, 203K against.","Approved non-binding advisory say-on-pay with 15.2M for, 7.2M against.","Approved amended certificate of incorporation to permit officer exculpation with 21.8M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294329,"accession_number":"0001370053-23-000039","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AnaptysBio reports Q1 net loss of $44.3M; initiates Phase 2b for ANB032 in atopic dermatitis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $44.3M ($1.58 per share) vs $36.3M loss in Q1 2022; R&D expenses rose to $35.0M.","Cash and investments totaled $526.1M; reiterated cash runway through year-end 2026.","Completed $50M stock repurchase program authorized in January 2023.","Initiated global Phase 2b trial for ANB032 (BTLA agonist) in moderate-to-severe atopic dermatitis; top-line data expected by year-end 2024.","Plans to start Phase 2b trial for rosnilimab in rheumatoid arthritis in Q3 2023 and second Phase 2 trial by year-end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":1374000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294328,"accession_number":"0001370053-23-000023","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2023-04-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AnaptysBio director Laura Hamill resigns; Rita Jain appointed to board and compensation committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laura J. Hamill resigned as Class II director effective April 1, 2023; no disagreement with company.","Rita Jain, M.D. appointed as Class II director and Compensation Committee member effective April 3, 2023.","Jain receives pro-rata annual retainer: option for 8,015 shares at April 3 closing price, 3,234 RSUs vesting at 2024 annual meeting.","Additional grants: option for 10,600 shares and 3,900 RSUs, each vesting over three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314938,"accession_number":"0001370053-23-000019","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AnaptysBio reports FY2022 net loss $128.7M; cash $584.2M; initiates Phase 2b trials for rosnilimab and ANB032","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2022 was $26.4M ($0.93 per share); full year net loss $128.7M ($4.57 per share), compared to $57.8M in 2021.","Cash, cash equivalents and investments totaled $584.2M as of Dec 31, 2022; cash runway through year-end 2026 reiterated.","Initiating global Phase 2b trial for rosnilimab (PD-1 agonist) in RA in Q3 2023; second Phase 2 trial in another indication by year-end 2023.","Initiating global Phase 2b trial for ANB032 (BTLA agonist) in atopic dermatitis in Q2 2023; top-line data expected year-end 2024.","Board authorized $50M stock repurchase plan in January 2023, expiring Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":10287000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314937,"accession_number":"0001370053-23-000013","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"AnaptysBio adopts amended bylaws to align with DGCL changes and universal proxy rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Second Amended and Restated Bylaws effective Feb 7, 2023; updates advance notice, proxy procedures, and exclusive forum clause.","Amendments conform to 2022 DGCL changes on adjournment, stockholder lists, and electronic notices; adds emergency bylaw provision.","Enhanced stockholder nomination requirements: limits nominees to board seats, mandates compliance with SEC Universal Proxy Rules (Rule 14a-19).","Exclusive forum clause designates federal district courts for Securities Act claims unless company consents otherwise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314936,"accession_number":"0001370053-23-000010","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2023-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"AnaptysBio authorizes $50M stock repurchase plan; cash >$575M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $50M of common stock through Dec 31, 2023.","Cash, equivalents, and investments >$575M as of Dec 31, 2022.","Reiterates ~4 years of capital to execute R&D plan, excluding potential GSK royalties.","Repurchases may occur in open market under Rule 10b5-1 and 10b-18; no obligation to buy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314935,"accession_number":"0001370053-23-000005","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AnaptysBio ends alopecia areata trial; launches Phase 2b for RA and atopic dermatitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rosnilimab Phase 2a in alopecia areata failed to achieve target efficacy (no patient SALT<20); further development discontinued.","Advancing rosnilimab (PD-1 agonist) into global Phase 2b for rheumatoid arthritis; initiates Q3 2023, top-line mid-2025.","Advancing ANB032 (BTLA agonist) into global Phase 2b for atopic dermatitis; initiates Q2 2023, top-line year-end 2024.","Cash and investments >$575M as of Dec 31, 2022; estimated ~4-year runway excluding GSK royalties.","Rosnilimab second Phase 2 trial in undisclosed indication expected by year-end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333294,"accession_number":"0001370053-22-000064","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AnaptysBio Q3 net loss $33.5M ($1.18/sh); cash $590.5M; alopecia areata data Q1 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.5M (Q3 2022) vs $6.7M (Q3 2021); loss/share $1.18 vs $0.24.","Cash & investments $590.5M as of Sep 30, 2022, down $24.7M from Dec 31, 2021.","Collaboration revenue fell to $1.3M (Q3 2022) from $20.9M (Q3 2021) on no GSK milestones.","Rosnilimab Phase 2 alopecia areata top-line data expected Q1 2023; ANB032 IND Q4 2022.","Zejula royalty sale to DRI for up to $45M ($35M upfront); GSK earned $5M milestone for cobolimab Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":3479000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350786,"accession_number":"0001370053-22-000052","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2022-09-12T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"AnaptysBio sells Zejula royalty rights to DRI Healthcare for $35M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $35M upfront from DRI for all future Zejula royalties from GSK (effective July 2022).","Eligible for additional $10M milestone if Zejula approved for endometrial cancer by Dec 31, 2025.","Current effective royalty rate is 0.5% of global Zejula net sales.","Agreement includes customary covenants; Purchase Agreement to be filed in Q3 2022 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350785,"accession_number":"0001370053-22-000049","cik":1370053,"company_name":"ANAPTYSBIO, INC","ticker":"ANAB","form_type":"8-K","filed_at":"2022-08-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Imsidolimab HARP Phase 2 fails to beat placebo in hidradenitis suppurativa; HS development halted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Imsidolimab did not improve primary endpoint (AN count change) or HiSCR50 vs placebo at Week 16 in moderate-to-severe HS.","No imsidolimab-related serious/severe AEs; safety profile acceptable across arms.","Company discontinues imsidolimab development in HS; GEMINI-1 Phase 3 for GPP continues with data expected Q4 2023.","Plans to outlicense imsidolimab prior to potential FDA approval for GPP; focus on rosnilimab and ANB032 immune cell modulators.","Cash over $570M at Q2 end; AZURE Phase 2 rosnilimab data in alopecia areata anticipated Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1706476885.7784712,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-31T23:59:59+00:00|350785"}